Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action-Reference-Cited by-同舟云学术

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action

Published:2022-02-23 Issue:5 Volume:65 Page:4350-4366
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Poddutoori Ramulu¹,Aardalen Kimberly²,Aithal Kiran¹,Barahagar Sanjeev Surendranath¹,Belliappa Charamanna¹,Bock Mark³,Chelur Shekar¹,Gerken Andrea³,Gopinath Sreevalsam¹,Gruenenfelder Bjoern⁴,Kiffe Michael⁴,Krishnaswami Maithreyi¹,Langowski John²,Madapa Sudharshan¹,Narayanan Kishore¹,Pandit Chetan¹,Panigrahi Sunil Kumar¹,Perrone Mark³,Potakamuri Ravi Kumar¹,Ramachandra Murali¹,Ramanathan Anuradha¹,Ramos Rita⁵,Sager Emine⁴,Samajdar Susanta¹^ORCID,Subramanya Hosahalli S.¹,Thimmasandra Devaraja Seethappa¹,Venetsanakos Eleni²,Möbitz Henrik⁴^ORCID

Affiliation:

1. Aurigene Discovery Technologies Ltd, 39-40 KIADB Industrial Area, Electronic City Phase II, Bengaluru 560100, India

2. Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States

3. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States

4. Novartis Institutes for BioMedical Research, Basel 4002, Switzerland

5. Global Drug Discovery, Novartis Pharma AG, Basel 4002, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02192